Magazine Article | February 1, 2021

CEO Q&A: Mary Szela

Source: Life Science Leader

By Dan Schell, Chief Editor, Clinical Leader

Mary Szela is president and CEO of TriSalus Life Sciences, an emerging immuno-oncology company developing treatments for patients with solid tumors. She has more than 30 years of biopharma experience, including spending 25 years at Abbott, where she held ascending management positions, including president of the company’s $8 billion U.S. pharmaceutical business. During the last seven years, she has held CEO positions at Melinta Pharmaceuticals, Novelion Therapeutics, and now TriSalus. With that kind of experience, we asked her to participate in the following Q&A to offer our readers some valuable insights about what it takes to transition from Big Pharma to a CEO position at a smaller biotech.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader